Showing results (101-110 of 143) with videos related to
Sort By:
Pageof 15
JCO Clinical Cancer Informatics|May 12, 2025
Prognostic Significance of the BALAD Serological Model in Systemic Therapies for Hepatocellular Carcinoma: A Personalized Approach to the Prediction of Survival BenefitHidenori Toyoda, Atsushi Hiraoka, Hironori Ochi, et al.Hepatology (Baltimore, Md.)|May 17, 2011
Effect of vitamin K2 on the recurrence of hepatocellular carcinomaHaruhiko Yoshida, Yasushi Shiratori, Masatoshi Kudo, et al.Journal of Gastroenterology|October 13, 2023
Posttreatment liver function, but not baseline liver function stratifies patient survival after direct-acting antiviral treatment in decompensated cirrhosis with hepatitis C virusYuki Tahata, Hayato Hikita, Satoshi Mochida, et al.Journal of Gastroenterology and Hepatology|January 6, 2025
Reliable Performance of mALBI Grade-Based Risk Models for Predicting the Prognosis of Patients With Hepatocellular Carcinoma Receiving Atezolizumab Plus Bevacizumab as First-Line Treatment: Comparative Analysis of 13 Risk ModelsTakeshi Hatanaka, Satoru Kakizaki, Atsushi Hiraoka, et al.Hepatology Research : the Official Journal of the Japan Society of Hepatology|June 12, 2023
Geriatric nutritional risk index as an easy-to-use assessment tool for nutritional status in hepatocellular carcinoma treated with atezolizumab plus bevacizumabAtsushi Hiraoka, Takashi Kumada, Toshifumi Tada, et al.Alimentary Pharmacology & Therapeutics|September 5, 2024
Predictive factors and survival outcome of conversion therapy for unresectable hepatocellular carcinoma patients receiving atezolizumab and bevacizumab: Comparative analysis of conversion, partial response and complete response patientsTakeshi Hatanaka, Satoru Kakizaki, Atsushi Hiraoka, et al.Cancer Medicine|January 22, 2025
Evaluation of Treatment Outcomes Using dNLR and GNRI in Combination Therapy With Atezolizumab and Bevacizumab for Hepatocellular CarcinomaAtsushi Naganuma, Satoru Kakizaki, Atsushi Hiraoka, et al.Hepatology Research : the Official Journal of the Japan Society of Hepatology|October 29, 2024
Factors involved in gastroesophageal varix-related events in patients with hepatitis C virus-related compensated and decompensated cirrhosis after direct-acting antiviral therapyYuki Tahata, Hayato Hikita, Satoshi Mochida, et al.Oncology|June 12, 2023
Lenvatinib as Second-Line Treatment after Atezolizumab plus Bevacizumab for Unresectable Hepatocellular Carcinoma: Clinical Results Show Importance of Hepatic Reserve FunctionAtsushi Hiraoka, Takashi Kumada, Toshifumi Tada, et al.Journal of Gastroenterology|August 1, 2023
Efficacy and safety of atezolizumab plus bevacizumab treatment for unresectable hepatocellular carcinoma patients with esophageal-gastric varicesFujimasa Tada, Atsushi Hiraoka, Toshifumi Tada, et al.Pageof 15